Chiesi Presented New Strategies to Customize the Management of COPD and Asthma During the ERS 2025 Congress in Amsterdam

Chiesi’s participation at the Congress of the European Respiratory Society (ERS) 2025, presented the latest advances in respiratory medicine, with an approach focused on the customization of treatments for chronic obstructive pulmonary disease (COPD) and asthma. The event, held between September 27 and October 1 in Amsterdam, brought together more than 20,000 health professionals and solidified its position as the largest European meeting in the respiratory field.

Chiesi’s participation was guided by the motto “Redefine expectations in respiratory patient care” with a complete scientific program that combined clinical innovation, research, and sustainability. The company organized three high-level symposia that addressed key issues in the management of chronic respiratory diseases.

Chiesi presented new strategies to customize the management of COPD and asthma during the ERS 2025 Congress in Amsterdam

The first symposium focused on redefining the control of COPD from a holistic approach. Experts analyzed the interaction between inflammation, small airway disease and comorbidities, highlighting the need to customize treatment strategies to improve disease stability and optimize long-term clinical results.

The second symposium approached personalized respiratory care, highlighting the importance of proper selection of the inhalation device.dry powder inhalers (DPI) and pressurized metered-dose inhalers (pMDI) were compared in terms of adherence, ease of use, and environmental sustainability. Additionally, the advantages of extrafine formulations were underlined, which allow for a more homogeneous distribution of the drug throughout the airway, especially in the small airways, frequently enough affected in these pathologies.